Brief Summary
A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and without any clinically significant evidence of disease progression with no access to venetoclax (not approved for the treated indication) may continue receiving venetoclax at the discretion of the investigator in a separate extension study.
Intervention / Treatment
- Drug: Venetoclax
- Drug: ethinyl estradiol/levonorgestrel
Inclusion Criteria
- Participant must have relapsed or refractory non-Hodgkin’s lymphomacancers of the lymphatic system (NHL).
- Participant must have histologically documented diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of one of the following NHL subtypes: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), T-cell prolymphocytic lymphoma (T-PLL), Waldenström’s macroglobulinemia (WM)
- Has an Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance score of less than or equal to two.
- Must have adequate bone marrowsoft, spongy tissue found in bones that makes blood cells, coagulation, renal and hepatic function as described in the protocol.
- A female of non-childbearing potential as described in the protocol.